{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:05:40Z","timestamp":1790165140224,"version":"4.1.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T00:00:00Z","timestamp":1771113600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Prostate International"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.prnil.2026.02.002","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T07:52:34Z","timestamp":1771919554000},"page":"217-224","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patients with high-risk features on active surveillance for prostate cancer"],"prefix":"10.1016","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3273-0161","authenticated-orcid":false,"given":"Sophie","family":"Goodman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8490-1743","authenticated-orcid":false,"given":"Yajat","family":"Dua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry Y.C.","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin","family":"Perera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niranjan","family":"Sathianathen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlon","family":"Perera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Declan","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Lawrentschuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prnil.2026.02.002_bib1","series-title":"Presented at the EAU annual congress Milan","article-title":"978-94-92671-19-6 EGEpatEACMI. EAU guidelines","year":"2023"},{"issue":"10","key":"10.1016\/j.prnil.2026.02.002_bib2","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","article-title":"Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Schaeffer","year":"2023","journal-title":"J Natl Compr Cancer Netw"},{"issue":"15","key":"10.1016\/j.prnil.2026.02.002_bib3","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1056\/NEJMoa1606220","article-title":"10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer","volume":"375","author":"Hamdy","year":"2016","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.prnil.2026.02.002_bib4","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1002\/ijc.29538","article-title":"Prevalence of incidental prostate cancer: a systematic review of autopsy studies","volume":"137","author":"Bell","year":"2015","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.prnil.2026.02.002_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00345-020-03523-2","article-title":"Overdiagnosis in urologic cancer : for world journal of urology symposium on active surveillance in prostate and renal cancer","volume":"40","author":"Klotz","year":"2022","journal-title":"World J Urol"},{"issue":"3","key":"10.1016\/j.prnil.2026.02.002_bib6","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/MOU.0000000000000157","article-title":"Observational studies and the natural history of screen-detected prostate cancer","volume":"25","author":"Albertsen","year":"2015","journal-title":"Curr Opin Urol"},{"issue":"3","key":"10.1016\/j.prnil.2026.02.002_bib7","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/JU.0000000000003097","article-title":"Long-term outcomes following active surveillance of low-grade prostate cancer: a population-based study using a landmark approach","volume":"209","author":"Timilshina","year":"2023","journal-title":"J Urol"},{"issue":"9","key":"10.1016\/j.prnil.2026.02.002_bib8","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.31015","article-title":"Long-term outcomes among men undergoing active surveillance for prostate cancer in Sweden","volume":"5","author":"Ventimiglia","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"6","key":"10.1016\/j.prnil.2026.02.002_bib9","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.eururo.2019.09.020","article-title":"EAU-EANM-ESTRO-ESUR-SIOG prostate cancer guideline panel consensus statements for deferred treatment with curative intent for localised prostate cancer from an international collaborative study (DETECTIVE study)","volume":"76","author":"Lam","year":"2019","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.prnil.2026.02.002_bib10","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/JU.0000000000002757","article-title":"Clinically localized prostate cancer: AUA\/ASTRO guideline, part I: introduction, risk assessment, staging, and risk-based management","volume":"208","author":"Eastham","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.prnil.2026.02.002_bib11","series-title":"Prostate cancer: diagnosis and management","year":"2019"},{"issue":"5","key":"10.1016\/j.prnil.2026.02.002_bib12","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/j.1464-410X.2010.10024.x","article-title":"The influence of family history on prostate cancer risk: implications for clinical management","volume":"107","author":"Madersbacher","year":"2011","journal-title":"BJU Int"},{"issue":"4","key":"10.1016\/j.prnil.2026.02.002_bib13","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/pros.2990170409","article-title":"Family history and the risk of prostate cancer","volume":"17","author":"Steinberg","year":"1990","journal-title":"Prostate"},{"issue":"2","key":"10.1016\/j.prnil.2026.02.002_bib14","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s00345-011-0801-1","article-title":"Familial risk and familial survival in prostate cancer","volume":"30","author":"Hemminki","year":"2012","journal-title":"World J Urol"},{"issue":"4","key":"10.1016\/j.prnil.2026.02.002_bib15","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/bju.13310","article-title":"A positive family history as a risk factor for prostate cancer in a population-based study with organised prostate-specific antigen screening: results of the Swiss European randomised study of screening for prostate cancer (ERSPC, Aarau)","volume":"117","author":"Randazzo","year":"2016","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.prnil.2026.02.002_bib16","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.eururo.2019.08.025","article-title":"Prostate cancer risks for Male BRCA1 and BRCA2 mutation carriers: a prospective cohort study","volume":"77","author":"Nyberg","year":"2020","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.prnil.2026.02.002_bib17","doi-asserted-by":"crossref","first-page":"315","DOI":"10.4111\/icu.20240053","article-title":"Impact of family history of prostate cancer on disease progression for prostatic cancer patients undergoing active surveillance: a systematic review and meta-analysis","volume":"65","author":"Jeon","year":"2024","journal-title":"Investig Clin Urol"},{"issue":"5","key":"10.1016\/j.prnil.2026.02.002_bib18","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.euo.2023.02.014","article-title":"Is active surveillance an option for the management of men with low-grade prostate cancer and a positive family history? Results from a large, single-institution series","volume":"6","author":"Leni","year":"2023","journal-title":"Eur Urol Oncol"},{"issue":"2","key":"10.1016\/j.prnil.2026.02.002_bib19","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/JU.0000000000002668","article-title":"Association of family history of cancer with clinical and pathological outcomes for prostate cancer patients on active surveillance","volume":"208","author":"Jibara","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.prnil.2026.02.002_bib20","unstructured":"Azari S, Mason JB, Kenigsberg AP, Koller C, Parikh S, Azar W, et al."},{"issue":"6","key":"10.1016\/j.prnil.2026.02.002_bib21","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1097\/JU.0000000000001307","article-title":"PI-RADS\u00ae category as a predictor of progression to unfavorable risk prostate cancer in men on active surveillance","volume":"204","author":"Wang","year":"2020","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.prnil.2026.02.002_bib22","first-page":"11955","article-title":"MRI-based PI-RADS score predicts ISUP upgrading and adverse pathology at radical prostatectomy in men with biopsy ISUP 1 prostate cancer","volume":"31","author":"Dekalo","year":"2024","journal-title":"Can J Urol"},{"issue":"3","key":"10.1016\/j.prnil.2026.02.002_bib23","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.eururo.2020.03.035","article-title":"Five-year outcomes of magnetic resonance imaging-based active surveillance for prostate cancer: a large cohort study","volume":"78","author":"Stavrinides","year":"2020","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.prnil.2026.02.002_bib25","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/JU.0000000000002758","article-title":"Clinically localized prostate cancer: AUA\/ASTRO guideline, part II: principles of active surveillance, principles of surgery, and follow-up","volume":"208","author":"Eastham","year":"2022","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.prnil.2026.02.002_bib24","doi-asserted-by":"crossref","first-page":"620","DOI":"10.2214\/AJR.17.17790","article-title":"Monitoring tumor volume in patients with prostate cancer undergoing active surveillance: is MRI apparent diffusion coefficient indicative of tumor growth?","volume":"209","author":"Morgan","year":"2017","journal-title":"Am J Roentgenol"},{"issue":"8","key":"10.1016\/j.prnil.2026.02.002_bib27","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.humpath.2007.01.006","article-title":"The relationship between the extent of surgical margin positivity and prostate specific antigen recurrence in radical prostatectomy specimens","volume":"38","author":"Marks","year":"2007","journal-title":"Hum Pathol"},{"issue":"5","key":"10.1016\/j.prnil.2026.02.002_bib26","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.juro.2015.04.113","article-title":"Baseline perineural invasion is associated with shorter time to progression in men with prostate cancer undergoing active surveillance: results from the REDEEM study","volume":"194","author":"Moreira","year":"2015","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.prnil.2026.02.002_bib28","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.euo.2022.07.004","article-title":"Active surveillance for intermediate-risk prostate cancer: a systematic review, meta-analysis, and metaregression","volume":"5","author":"Baboudjian","year":"2022","journal-title":"Eur Urol Oncol"},{"issue":"4","key":"10.1016\/j.prnil.2026.02.002_bib29","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1097\/JU.0000000000002354","article-title":"Evaluating the outcomes of active surveillance in grade group 2 prostate cancer: prospective results from the canary PASS cohort","volume":"207","author":"Waisman Malaret","year":"2022","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.prnil.2026.02.002_bib30","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1097\/JU.0000000000000742","article-title":"Risk of metastasis in men with grade group 2 prostate cancer managed with active surveillance at a tertiary cancer center","volume":"203","author":"Carlsson","year":"2020","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.prnil.2026.02.002_bib31","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41391-024-00888-y","article-title":"Active surveillance selection and 3-year durability in intermediate-risk prostate cancer following genomic testing","volume":"28","author":"Lenz","year":"2025","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"2","key":"10.1016\/j.prnil.2026.02.002_bib32","doi-asserted-by":"crossref","first-page":"218","DOI":"10.7326\/ANNALS-24-00700","article-title":"Impact of genomic classifiers on risk stratification and treatment intensity in patients with localized prostate cancer","volume":"178","author":"Tabriz","year":"2025","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.prnil.2026.02.002_bib33","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41391-018-0074-5","article-title":"Role of the 4Kscore test as a predictor of reclassification in prostate cancer active surveillance","volume":"22","author":"Borque-Fernando","year":"2019","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"5","key":"10.1016\/j.prnil.2026.02.002_bib34","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1097\/JU.0000000000002852","article-title":"Impact of prostate health index results for prediction of biopsy grade reclassification during active surveillance","volume":"208","author":"Filson","year":"2022","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.prnil.2026.02.002_bib35","first-page":"149","article-title":"Clinical performance of the 4Kscore test to predict high-grade prostate cancer at biopsy: a meta-analysis of Us and European clinical validation study results","volume":"19","author":"Zappala","year":"2017","journal-title":"Rev Urol"},{"issue":"14","key":"10.1016\/j.prnil.2026.02.002_bib36","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1002\/pros.23401","article-title":"A urinary biomarker-based risk score correlates with multiparametric MRI for prostate cancer detection","volume":"77","author":"Hendriks","year":"2017","journal-title":"Prostate"},{"issue":"1","key":"10.1016\/j.prnil.2026.02.002_bib37","doi-asserted-by":"crossref","first-page":"393","DOI":"10.21873\/invivo.11786","article-title":"Multiparametric MRI versus SelectMDx accuracy in the diagnosis of clinically significant PCa in men enrolled in active surveillance","volume":"34","author":"Pepe","year":"2020","journal-title":"In Vivo"},{"issue":"2","key":"10.1016\/j.prnil.2026.02.002_bib38","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/s41391-022-00538-1","article-title":"Accuracy of SelectMDx compared to mpMRI in the diagnosis of prostate cancer: a systematic review and diagnostic meta-analysis","volume":"25","author":"Sari","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.prnil.2026.02.002_bib39","article-title":"Systematic review of cost-effectiveness models in prostate cancer: exploring new developments in testing and diagnosis","volume":"25","author":"Keeney","year":"2021","journal-title":"Value Health"},{"key":"10.1016\/j.prnil.2026.02.002_bib40","unstructured":"MBS online [internet]. Australian Government. [cited 06\/01\/2026]."},{"issue":"9","key":"10.1016\/j.prnil.2026.02.002_bib41","doi-asserted-by":"crossref","DOI":"10.1200\/PO-25-00406","article-title":"Sociodemographic features, health care costs, and treatment implications of genomic classifier testing for localized prostate cancer in the United States","author":"Janopaul-Naylor","year":"2025","journal-title":"JCO Precis Oncol"},{"issue":"14","key":"10.1016\/j.prnil.2026.02.002_bib42","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.3390\/cancers17142334","article-title":"The role of genomic scores in the management of prostate cancer patients: a comprehensive narrative review","volume":"17","author":"Viti","year":"2025","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.prnil.2026.02.002_bib43","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.euo.2023.05.004","article-title":"Gallium-68 prostate-specific membrane antigen positron emission tomography\/computed tomography in active surveillance for prostate cancer trial (PASPoRT)","volume":"7","author":"Heetman","year":"2024","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"10.1016\/j.prnil.2026.02.002_bib44","doi-asserted-by":"crossref","DOI":"10.3390\/life14010076","article-title":"A systematic review on prostate-specific membrane antigen positron emission tomography (PSMA PET) evaluating localized Low- to intermediate-risk prostate cancer: a tool to improve risk stratification for active surveillance?","volume":"14","author":"Liu","year":"2024","journal-title":"Life"},{"issue":"14","key":"10.1016\/j.prnil.2026.02.002_bib45","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1002\/pros.24595","article-title":"Immunohistochemical and histopathological validation of (18) F-PSMA-1007 PET\/CT for intraprostatic cancerous lesions","volume":"83","author":"Heetman","year":"2023","journal-title":"Prostate"},{"issue":"3","key":"10.1016\/j.prnil.2026.02.002_bib46","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.21873\/invivo.13211","article-title":"(68)Ga-PSMA PET\/CT and prostate cancer diagnosis: which SUVmax value?","volume":"37","author":"Heetman","year":"2023","journal-title":"In Vivo"},{"issue":"2","key":"10.1016\/j.prnil.2026.02.002_bib47","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/JU.0000000000002254","article-title":"(68)Ga-Prostate-Specific membrane antigen positron emission tomography maximum standardized uptake value as a predictor of gleason pattern 4 and pathological upgrading in intermediate-risk prostate cancer","volume":"207","author":"Xue","year":"2022","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.prnil.2026.02.002_bib48","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.euo.2025.02.010","article-title":"Early results from the CONFIRM trial: utility of prostate-specific membrane antigen positron emission tomography\/computed tomography in active surveillance for prostate cancer","volume":"8","author":"Liu","year":"2025","journal-title":"Eur Urol Oncol"},{"issue":"Suppl 4","key":"10.1016\/j.prnil.2026.02.002_bib49","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/bju.16214","article-title":"The CONFIRM trial protocol: the utility of prostate-specific membrane antigen positron emission tomography\/computed tomography in active surveillance for prostate cancer","volume":"133","author":"Bagguley","year":"2024","journal-title":"BJU Int"},{"issue":"6","key":"10.1016\/j.prnil.2026.02.002_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2024.102204","article-title":"Quantification of gleason pattern 4 metrics identifies pathologic progression in patients with grade group 2 prostate cancer on active surveillance","volume":"22","author":"Perera","year":"2024","journal-title":"Clin Genitourin Cancer"},{"issue":"2","key":"10.1016\/j.prnil.2026.02.002_bib51","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/JU.0000000000002685","article-title":"Oncologic outcomes of total length gleason pattern 4 on biopsy in men with grade group 2 prostate cancer","volume":"208","author":"Perera","year":"2022","journal-title":"J Urol"},{"issue":"22","key":"10.1016\/j.prnil.2026.02.002_bib52","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics14222576","article-title":"Systematic review of AI-Assisted MRI in prostate cancer diagnosis: enhancing accuracy through second opinion tools","volume":"14","author":"Alqahtani","year":"2024","journal-title":"Diagnostics"},{"issue":"1","key":"10.1016\/j.prnil.2026.02.002_bib53","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s41747-023-00321-4","article-title":"Beyond diagnosis: is there a role for radiomics in prostate cancer management?","volume":"7","author":"Stanzione","year":"2023","journal-title":"European Radiology Experimental"},{"issue":"4","key":"10.1016\/j.prnil.2026.02.002_bib54","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.prnil.2025.02.002","article-title":"Artificial intelligence\u2013driven digital pathology in urological cancers: current trends and future directions","volume":"13","author":"Paik","year":"2025","journal-title":"Prostate International"},{"issue":"6","key":"10.1016\/j.prnil.2026.02.002_bib55","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1097\/JU.0000000000003396","article-title":"Impact of an expanded definition of family history on outcomes of active surveillance for prostate cancer","volume":"209","author":"Schneider","year":"2023","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.prnil.2026.02.002_bib56","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1097\/JU.0000000000001941","article-title":"The risk of prostate cancer progression in active surveillance patients with bilateral disease detected by combined magnetic resonance imaging-fusion and systematic biopsy","volume":"206","author":"Williams","year":"2021","journal-title":"J Urol"},{"issue":"6_suppl","key":"10.1016\/j.prnil.2026.02.002_bib57","doi-asserted-by":"crossref","first-page":"TPS397","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS397","article-title":"PRIMARY2: a phase III, multi-centre, randomised controlled trial investigating the additive diagnostic value of [68Ga]Ga-PSMA-11 PET\/CT in men with negative\/equivocal MRI in the diagnosis of clinically significant prostate cancer","volume":"41","author":"Buteau","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["Prostate International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2287888226000061?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2287888226000061?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:46:33Z","timestamp":1790163993000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2287888226000061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":57,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2287888226000061"],"URL":"https:\/\/doi.org\/10.1016\/j.prnil.2026.02.002","relation":{},"ISSN":["2287-8882"],"issn-type":[{"value":"2287-8882","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patients with high-risk features on active surveillance for prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Prostate International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prnil.2026.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Asian Pacific Prostate Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}